Jianyibao

Jianyibao, founded in 2017 in Beijing, is the first comprehensive service platform in China to systematically engage in risk and health management for populations with pre-existing conditions. By successfully connecting pharmaceutical companies, medication usage scenarios, and financial insurance companies, Jianyibao addresses cross-industry pain points among these three sectors through its core capabilities of professionalism, technology, and innovation. Collaborating with insurance companies, Jianyibao develops insurable products tailored for populations with pre-existing conditions, resolving their health coverage issues.Since its establishment, Jianyibao has launched several commercial insurance products targeting specific patient groups, including "Xinyibao," a comprehensive chronic disease protection plan; "Jielibao," a coverage plan for patients with multiple sclerosis; and "Youjia Ai Long-term Cancer Insurance" (available for post-operative thyroid cancer patients). These initiatives have achieved multiple industry-first innovations, improving the lives of hundreds of thousands of patients by addressing the issue of "poverty due to illness and returning to poverty because of illness," restoring hope for many.With its mature and forward-thinking business model, Jianyibao has garnered significant attention and recognition from investment institutions. In less than two years since its founding, it received multiple rounds of investments from Puhua Capital and Baidu Ventures. In December 2019, Jianyibao completed a multi-million yuan Series A+ round led by Zhongji Investment, with Weilai Capital participating as a follow-up investor. Additionally, Jianyibao has been extensively covered by authoritative media outlets, including People's Daily Online, Xinhua Net, China Insurance News, and the 21st Century Business Herald.